Clinical Trials Logo

Migraine With or Without Aura clinical trials

View clinical trials related to Migraine With or Without Aura.

Filter by:

NCT ID: NCT06245902 Completed - Clinical trials for Migraine With or Without Aura

An Acute Migraine Factorial Study

ANODYNE-1
Start date: February 18, 2017
Phase: Phase 2
Study type: Interventional

The study consists of a screening visit, out-patient treatment of a moderate or severe migraine attack with a single dose of the study medication within 8 weeks, and End-of-Study Visit 2-7 days after dosing.

NCT ID: NCT03461757 Completed - Clinical trials for Migraine, With or Without Aura

Trial in Adult Subjects With Acute Migraines

Start date: February 27, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant ODT) versus placebo in subjects with Acute Migraines.

NCT ID: NCT03266588 Completed - Clinical trials for Migraine, With or Without Aura

Open Label Safety Study in Acute Treatment of Migraine

Start date: August 30, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate safety and tolerability of BHV-3000 (rimegepant).

NCT ID: NCT03237845 Completed - Clinical trials for Migraine, With or Without Aura

Safety and Efficacy in Adult Subjects With Acute Migraines

Start date: July 27, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant) versus placebo in subjects with Acute Migraines

NCT ID: NCT03235479 Completed - Clinical trials for Migraine, With or Without Aura

Safety and Efficacy Study in Adult Subjects With Acute Migraines

Start date: July 18, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant) versus placebo in subjects with Acute Migraines

NCT ID: NCT03194555 Completed - Clinical trials for Migraine With or Without Aura

The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination

Start date: August 25, 2017
Phase: Phase 2
Study type: Interventional

The Preventive Treatment of Migraine with Low-Dose Naltrexone and Acetaminophen Combination: A Small, Randomized, Double-Blind, and Placebo-Controlled Clinical Trial with an Open-Label Extension for None-Responders

NCT ID: NCT03061734 Completed - Clinical trials for Migraine With or Without Aura

Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine

ANODYNE-1
Start date: February 18, 2017
Phase: Phase 2
Study type: Interventional

The study consists of a screening visit, out-patient treatment of a moderate or severe migraine attack with a single dose of the study medication within 8 weeks, and End-of-Study Visit 2-7 days after dosing.

NCT ID: NCT02873221 Completed - Clinical trials for Migraine, With or Without Aura

An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine

Start date: September 13, 2016
Phase: Phase 3
Study type: Interventional

This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.

NCT ID: NCT02867709 Completed - Clinical trials for Migraine, With or Without Aura

Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

ACHIEVE II
Start date: August 26, 2016
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.

NCT ID: NCT02848326 Completed - Clinical trials for Migraine, With or Without Aura

Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention

Start date: September 6, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

This study will evaluate the safety and tolerability of the following doses of atogepant (AGN-241689): 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and will characterize the dose/response relationship.